Evaluating only Verily Life Sciences’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. That’s exactly how it died.
Key Events Timeline
PRODUCT LAUNCH
Spun out from Google X as Verily Life Sciences
FUNDING
Raised $800M from TPG; smart lens project with Novartis
PRODUCT LAUNCH
Smart lens project abandoned; Study Watch launched
FUNDING
Raised $1B more; multiple drug discovery shutdowns
LAYOFF
15% layoff (240 people); pivot to narrower commercial focus
Full Analysis
Free · no account needed
Documented cause
Verily Life Sciences was Alphabet's life sciences subsidiary, spun out of Google X in 2015 with a mission to transform medicine through technology — smart contact lenses for diabetics, wearable continuous health monitoring, precision medicine platforms, and disease studies. It raised over $1.8 billion from investors including TPG and Silver Lake in addition to Alphabet's own capital. After nearly a decade, Verily had failed to commercialize most of its flagship products: the smart contact lens (developed with Novartis) was abandoned, multiple drug discovery programs were shut down, and its Study Watch never reached mass market. In January 2023, Verily laid off approximately 15% of its workforce — around 240 people — and disclosed it was pivoting to focus on a narrower set of commercial opportunities.
Lesson
“Healthcare moonshots face a fundamental timing paradox: the FDA approval timelines required to commercialize breakthrough medical technology are 5-10x longer than the product iteration cycles that Silicon Valley investors expect. Even Alphabet's patience has limits.”